# Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

> **NCT02411708** · PHASE2 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** SANGUINATE
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02411708
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411708, "Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02411708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*